About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Growth Hormone Analog Could Reduce the Risk of Fatty Liver Disease in HIV-infected Patients

by Dr. Enozia Vakil on July 21, 2014 at 1:04 PM
Font : A-A+

 Growth Hormone Analog Could Reduce the Risk of Fatty Liver Disease in HIV-infected Patients

Modest reduction in liver fat was seen in HIV patients having excess abdominal fat after they received a growth hormone releasing hormone analog for six months, a new study has found. Patients infected with HIV demonstrate a high prevalence of nonalcoholic fatty liver disease, estimated at 30 percent to 40 percent. The issue is being released early to coincide with the International AIDS Conference.

In human immunodeficiency virus (HIV) infection, abdominal fat accumulation is associated with ectopic (out of place) fat accumulation in the liver. Nonalcoholic fatty liver disease (NAFLD) may progress to end-stage liver disease and liver cancer. To date, there are no approved pharmacologic strategies to reduce liver fat. Tesamorelin specifically targets abdominal fat reduction but its effects on liver fat are unknown, according to background information in the article.

Advertisement

Takara L. Stanley, M.D., of Massachusetts General Hospital and Harvard Medical School, Boston, and colleagues randomly assigned 50 antiretroviral-treated HIV-infected men and women with abdominal fat accumulation to receive tesamorelin (n=28), or placebo (n=22), subcutaneously daily for 6 months.

The researchers found a modest but statistically significant decrease in liver fat with tesamorelin. Hepatic lipid to water percentage (a measure of liver fat), decreased in the tesamorelin group (median, -2.0 percent) compared with placebo (median, 0.9 percent). In addition, there was a significant reduction in abdominal fat: the average change was -9.9 percent with tesamorelin vs 6.6 percent with placebo.
Advertisement

"The decrease in liver fat in this study suggests that strategies to reduce visceral adiposity merit further investigation in HIV-infected patients with NAFLD, a condition for which there are no approved treatments. Importantly, NAFLD is associated with visceral adiposity and other metabolic abnormalities in HIV," the authors write.

"Further studies are needed to determine the clinical importance and long-term consequences of these findings."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Baldness can be Cured and Prevented: let us see How!
Drinking Beer or Wine Every Day Could Cause Age-related Diseases
Low-Calorie Diet for Diabetes
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Alcoholic Liver Disease Liver Biopsy Hepatitis A Acromegaly Grow as tall as you want Does Yoga help you grow Taller Liver Wilson's Disease Biliary Cirrhosis Milk Thistle 

Most Popular on Medindia

Noscaphene (Noscapine) Find a Doctor Accident and Trauma Care Color Blindness Calculator Calculate Ideal Weight for Infants Pregnancy Confirmation Calculator Selfie Addiction Calculator Indian Medical Journals Blood Donation - Recipients A-Z Drug Brands in India
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use